RxDoctor Payments Data

Deval Mehta, MD

Interventional Cardiology · Burleson, TXNPI 1437376795

Payments from drug & device makers

$143,797in general payments, 2019–2025

Across 243 payments — averaging $591.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scientia Vascular$138K
  • Abbott$2K
  • Pfizer$608
  • Novartis$551
  • Johnson & Johnson$339
  • Philips North America LLC$314
  • plus $2K from 30 others

What the payments were for

  • Travel & lodging$87315%
  • Food & beverage$4,99085%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$143,797 in reported general payments places this provider in the 85th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$592,013
Medicare patients
963
Services billed
4,982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban546$540,212
XareltoRivaroxaban108$97,723
EntrestoSacubitril/Valsartan74$82,113
FarxigaDapagliflozin Propanediol73$54,574
JardianceEmpagliflozin55$48,165
Repatha SureclickEvolocumab36$30,662
BrilintaTicagrelor22$11,570
Rosuvastatin Calcium681$6,594
ClopidogrelClopidogrel Bisulfate567$5,772
VascepaIcosapent Ethyl12$4,183
Ezetimibe306$4,104
Atorvastatin Calcium362$3,390
Metoprolol Succinate231$3,335
Ranolazine ErRanolazine49$3,023
Midodrine Hcl38$2,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$608$540,212546 claims
Johnson & JohnsonXarelto$339$97,723108 claims
NovartisEntresto$551$82,11374 claims
AstraZenecaFarxiga, Brilinta$277$66,14495 claims
Boehringer IngelheimJardiance$14$48,16555 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →